S1P agonist
Sphingosine-1-phosphate receptor agonist
- Persistent S1P₁ internalization → functional antagonism
- Lymphocytes are trapped in lymph nodes
- Fewer circulating lymphocytes reach the CNS and gut → treats MS and IBD
- First-dose bradycardia, macular edema and infection risk are class effects
- Sphingosine-1-phosphate receptor signaling
Drugs with this mechanism (5)
- Etrasimod — Oral selective S1P-receptor modulator for ulcerative colitis; no titration is needed.
- Fingolimod — First oral MS drug; traps lymphocytes in nodes, with first-dose bradycardia.
- Ozanimod — Oral S1P1/S1P5 modulator for relapsing multiple sclerosis and ulcerative colitis.
- Ponesimod — Selective S1P1 modulator for relapsing multiple sclerosis; sequesters lymphocytes, with initiation-related bradycardia and infection risks.
- Siponimod — S1P1/S1P5 modulator for active secondary-progressive MS; CYP2C9 genotype determines eligibility.
All mechanisms · Open S1P agonist in the interactive console ↗